ASCO GU 2017: Cryoablation of cT1 renal masses in the “healthy” patient: Early outcomes from Mayo Clinic. - Session Highlights

Orlando, Florida USA (UroToday.com) The management of the clinical stage T1 renal mass has received much attention at this year’s ASCO Genitourinary Symposium. In this session, Dr. Zaid presented a single institution cohort from the Mayo Clinic looking at cryoablation in “healthy” patients from 2003-2015. Inclusion criteria were patient ≤ 65 years old, solitary, non-metastatic renal masses < 7 cm, American Society of Anesthesiologist (ASA) score of 1 or 2, and pre-procedure glomerular filtration rate (GFR) of > 60. Patients with hereditary renal cell carcinoma syndromes were excluded.

A total of 43 patients (6.1% of total ablative database) met inclusion criteria. The median age was 57 years (IQR 52-62) and pre-ablation GFR was 75.6 (IQR 69-86.3). The cryoablation technique involves anesthetizing the patient and using real-time ultrasound or computed tomography (CT) guidance for probe placement. Approximately 1 probe for each 1 cm of tumor is used and 1-2 cm spacing between probes is utilized. One or two 18-gauge core biopsies are performed and a freeze-thaw-freeze cycle of 10 minutes-5 minutes-10 minutes is performed. CT imaging is done every 2-4 minutes during freeze cycles to monitor the ice ball and immediate post-ablation imaging is routinely performed to evaluate for complications and ensure technical success. Follow-up imaging is obtained at 3- and 6-months post-ablation and every 6-12 months after depending on clinical and patient factors.

Median radiological follow-up was 22 months (IQR 9-42). One patient (2.3%) developed local recurrence and two (4.6%) developed metastatic disease. Both patients who developed metastatic disease had a prior nephrectomy for high-risk pathology. The patient who developed a recurrence underwent repeat ablation and is currently without recurrence. No patients died from RCC during the study timeframe.

Dr. Zaid concluded that cryoablation has good short term oncologic outcomes and an excellent safety profile. Further, there is a potential role for repeat ablation following local recurrence. Cryoablation in healthier patients – particularly those with challenging surgical anatomy or prior kidney surgery – warrants continued prospective analysis.

First author: Harras Zaid, MD, Mayo Clinic

Written By: Shreyas Joshi, MD, Fox Chase Cancer Center

at the 2017 Genitourinary Cancers Symposium - February 16 - 18, 2017 – Orlando, Florida USA
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe